RU2020102454A - Композиции для профилактики и лечения острого повреждения почек - Google Patents
Композиции для профилактики и лечения острого повреждения почек Download PDFInfo
- Publication number
- RU2020102454A RU2020102454A RU2020102454A RU2020102454A RU2020102454A RU 2020102454 A RU2020102454 A RU 2020102454A RU 2020102454 A RU2020102454 A RU 2020102454A RU 2020102454 A RU2020102454 A RU 2020102454A RU 2020102454 A RU2020102454 A RU 2020102454A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- ngal
- recombinantly produced
- drug
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 14
- 238000011282 treatment Methods 0.000 title claims 10
- 230000002265 prevention Effects 0.000 title claims 3
- 230000001154 acute effect Effects 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
- 229940079593 drug Drugs 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 7
- 230000013595 glycosylation Effects 0.000 claims 7
- 238000006206 glycosylation reaction Methods 0.000 claims 7
- 229920001661 Chitosan Polymers 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 6
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 5
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 claims 5
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims 5
- 102000013519 Lipocalin-2 Human genes 0.000 claims 5
- 108010051335 Lipocalin-2 Proteins 0.000 claims 5
- 208000033626 Renal failure acute Diseases 0.000 claims 5
- 201000011040 acute kidney failure Diseases 0.000 claims 5
- 102000047202 human LCN2 Human genes 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 claims 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 3
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 claims 3
- 229960004352 diosmin Drugs 0.000 claims 3
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 claims 3
- 230000003449 preventive effect Effects 0.000 claims 3
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims 2
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims 2
- 239000000890 drug combination Substances 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical class 0.000 claims 2
- 235000017709 saponins Nutrition 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims 1
- XZDDMPMZGYEESG-VNHFGJPGSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-12-(2-hydroxyethoxymethyl)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,15,19,25,28-octamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritr Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](COCCO)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O XZDDMPMZGYEESG-VNHFGJPGSA-N 0.000 claims 1
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims 1
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 claims 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 claims 1
- 102000013382 Gelatinases Human genes 0.000 claims 1
- 108010026132 Gelatinases Proteins 0.000 claims 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 108010014251 Muramidase Proteins 0.000 claims 1
- 102000016943 Muramidase Human genes 0.000 claims 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims 1
- 240000005373 Panax quinquefolius Species 0.000 claims 1
- JFACETXYABVHFD-WXPPGMDDSA-N Pristimerin Chemical compound CC1=C(O)C(=O)C=C2[C@@](CC[C@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C[C@H]53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-WXPPGMDDSA-N 0.000 claims 1
- FMPJNBPZCVETGY-UHFFFAOYSA-N Pristimerinen Natural products C12=CC=C3C(C)=C(O)C(=O)C=C3C2=C(C)CC2(C)C1(C)CCC1(C)CCC(C(=O)OC)(C)CC12 FMPJNBPZCVETGY-UHFFFAOYSA-N 0.000 claims 1
- 108010033973 SDZ IMM 125 Proteins 0.000 claims 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 108010019249 cyclosporin G Proteins 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims 1
- 229940025878 hesperidin Drugs 0.000 claims 1
- 229960000274 lysozyme Drugs 0.000 claims 1
- 235000010335 lysozyme Nutrition 0.000 claims 1
- 239000004325 lysozyme Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 229950010646 oxeclosporin Drugs 0.000 claims 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 claims 1
- IXWGHMMOEFOOFA-UHFFFAOYSA-N pristimerin Natural products COC(=O)C1(C)CCC2(C)CCC3(C)C4CC=C5C(=C(O)C(=O)C=C5C4(C)CCC3(C)C2C1)C IXWGHMMOEFOOFA-UHFFFAOYSA-N 0.000 claims 1
- JFACETXYABVHFD-UHFFFAOYSA-N pristimerine Natural products CC1=C(O)C(=O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-UHFFFAOYSA-N 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Композиция, включающая лекарственное средство, выбранное из перечня, включающего представителей семейства циклоспоринов, включая оксеклоспорин, и нециклоспориновые соединения такролимус, серолимус и эверолимус, где указанное лекарственное средство конъюгировано с липокалином, ассоциированным с желатиназой нейтрофилов, (NGAL), или с лизоцимом, или с низкомолекулярным хитозаном, и где конъюгат составлен для внутривенного введения для применения в профилактике и/или превентивном лечении и/или лечении острого повреждения почки у субъекта-человека.
2. Композиция по п. 1, где лекарственное средство представляет собой циклоспорин А, конъюгированный с рекомбинантно продуцируемым человеческим NGAL, в котором необязательно может отсутствовать гликозилирование и/или остаток цистеина в положении 87 его белковой цепи, или с рекомбинантно продуцируемым человеческим лизоцимом, или с низкомолекулярным хитозаном.
3. Композиция по п. 1, где лекарственное средство представляет собой циклоспорин G, конъюгированный с рекомбинантно продуцируемым человеческим NGAL, в котором необязательно может отсутствовать гликозилирование и/или остаток цистеина в положении 87 его белковой цепи, или с рекомбинантно продуцируемым человеческим лизоцимом, или с низкомолекулярным хитозаном.
4. Композиция по п. 1, где лекарственное средство представляет собой оксеклоспорин, конъюгированный с рекомбинантно продуцируемым человеческим NGAL, в котором необязательно может отсутствовать гликозилирование и/или остаток цистеина в положении 87 его белковой цепи, или с рекомбинантно продуцируемым человеческим лизоцимом, или с низкомолекулярным хитозаном.
5. Композиция по п. 1, где лекарственное средство выбрано из перечня, включающего такролимус, серолимус и эверолимус, и конъюгировано с рекомбинантно продуцируемым человеческим NGAL, в котором необязательно может отсутствовать гликозилирование и/или остаток цистеина в положении 87 его белковой цепи, или с рекомбинантно продуцируемым человеческим лизоцимом, или с низкомолекулярным хитозаном.
6. Композиция по любому из предшествующих пунктов, где NGAL находится в форме любого из NGAL, в котором отсутствует гликозилирование, или NGAL, в котором отсутствует остаток цистеина в положении 87, или NGAL, в котором отсутствует гликозилирование и отсутствует остаток цистеина в положении 87.
7. Композиция, включающая комбинацию лекарственных средств, составленных для внутривенного введения, для применения в профилактике и/или превентивном лечении и/или лечении острого повреждения почки у субъекта-человека, где комбинация состоит из пентациклического тритерпеноида, выбранного из перечня, включающего целастрол, пристимерин и бетулиновую кислоту, вместе с сапонином или флавоноидом, выбранным из перечня, включающего диосмин, гесперидин и сапонины из Panax quinquefolium.
8. Композиция по п. 7, где комбинация лекарственных средств включает бетулиновую кислоту и диосмин.
9. Композиция по п. 7, где комбинация лекарственных средств включает селастрол и диосмин.
10. Композиция по п. 8 или 9, где лекарственные средства конъюгированы с рекомбинантно продуцируемым человеческим NGAL, в котором необязательно может отсутствовать гликозилирование и/или остаток цистеина в положении 87 его белковой цепи, или с рекомбинантно продуцируемым человеческим лизоцимом, или с низкомолекулярным хитозаном, и где конъюгат составлен для внутривенного введения для применения в профилактике, и/или превентивном лечении, и/или лечении острого повреждения почки у субъекта-человека.
11. Композиция по любому из предшествующих пунктов для применения в профилактике, и/или превентивном лечении, и/или лечении острого повреждения почки, где композицию комбинируют с другим лекарственным средством.
12. Способ профилактики и/или превентивного лечения, и/или лечения острого повреждения почки, включающий внутривенное введение композиции, как определено в одном из пп. 1-10, субъекту, нуждающемуся в такой профилактике и/или лечении.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201770488 | 2017-06-23 | ||
| DKPA201770488 | 2017-06-23 | ||
| PCT/EP2018/066390 WO2018234372A1 (en) | 2017-06-23 | 2018-06-20 | COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ACUTE RENAL INJURY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020102454A true RU2020102454A (ru) | 2021-07-23 |
| RU2020102454A3 RU2020102454A3 (ru) | 2021-10-21 |
Family
ID=62748964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020102454A RU2020102454A (ru) | 2017-06-23 | 2018-06-20 | Композиции для профилактики и лечения острого повреждения почек |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11471445B2 (ru) |
| EP (1) | EP3641798A1 (ru) |
| JP (2) | JP2020524714A (ru) |
| CN (1) | CN110996985A (ru) |
| AU (1) | AU2018287044A1 (ru) |
| CA (1) | CA3067911A1 (ru) |
| IL (1) | IL271564B1 (ru) |
| RU (1) | RU2020102454A (ru) |
| WO (1) | WO2018234372A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112472792B (zh) * | 2020-12-28 | 2022-12-13 | 河北师范大学 | 环孢素a联合雷公藤红素在制备治疗肺癌药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070116761A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20020006901A1 (en) * | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| JP4272100B2 (ja) * | 2004-04-01 | 2009-06-03 | ポーラ化成工業株式会社 | くすみを改善する化粧料 |
| WO2005107793A2 (en) | 2004-05-06 | 2005-11-17 | The Trustees Of Columbia University | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| CN100546656C (zh) * | 2006-05-10 | 2009-10-07 | 四川大学 | 一种肾靶向药物载体及与其形成的前药、制法和应用 |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| US10190986B2 (en) * | 2011-06-06 | 2019-01-29 | Abbott Laboratories | Spatially resolved ligand-receptor binding assays |
| US10300108B2 (en) | 2013-12-03 | 2019-05-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2015108912A1 (en) | 2014-01-16 | 2015-07-23 | MUSC Foundation for Research and Development | Targeted nanocarriers for the administration of immunosuppressive agents |
| WO2016153920A1 (en) | 2015-03-20 | 2016-09-29 | Memorial Sloan Kettering Cancer Center | Mesoscale nanoparticles for selective targeting to the kidney and methods of their therapeutic use |
| WO2017100700A2 (en) | 2015-12-11 | 2017-06-15 | Fred Hutchinson Cancer Research Center | Peptides for renal therapy |
| KR101715294B1 (ko) * | 2016-06-09 | 2017-03-10 | 연세대학교 산학협력단 | 디오스민 또는 이의 염을 유효성분으로 함유하는 피부보습 개선, 피부각질 제거, 피부탄력 증진, 홍반 억제, 피부주름 개선 또는 피부광노화 개선 효과를 갖는 조성물 |
-
2018
- 2018-06-20 RU RU2020102454A patent/RU2020102454A/ru unknown
- 2018-06-20 US US16/624,858 patent/US11471445B2/en active Active
- 2018-06-20 CN CN201880050509.3A patent/CN110996985A/zh active Pending
- 2018-06-20 WO PCT/EP2018/066390 patent/WO2018234372A1/en active Application Filing
- 2018-06-20 CA CA3067911A patent/CA3067911A1/en active Pending
- 2018-06-20 AU AU2018287044A patent/AU2018287044A1/en active Pending
- 2018-06-20 EP EP18734160.7A patent/EP3641798A1/en active Pending
- 2018-06-20 JP JP2020520713A patent/JP2020524714A/ja active Pending
- 2018-06-20 IL IL271564A patent/IL271564B1/en unknown
-
2024
- 2024-02-16 JP JP2024022099A patent/JP2024069226A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024069226A (ja) | 2024-05-21 |
| IL271564B1 (en) | 2024-02-01 |
| EP3641798A1 (en) | 2020-04-29 |
| WO2018234372A1 (en) | 2018-12-27 |
| US20210330649A1 (en) | 2021-10-28 |
| CA3067911A1 (en) | 2018-12-27 |
| IL271564A (en) | 2020-02-27 |
| US11471445B2 (en) | 2022-10-18 |
| JP2020524714A (ja) | 2020-08-20 |
| AU2018287044A1 (en) | 2020-02-13 |
| RU2020102454A3 (ru) | 2021-10-21 |
| CN110996985A (zh) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015013695A2 (pt) | composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv | |
| BR112013005907A2 (pt) | composição farmacêutica parenteral, métodos para o tratamento e para prevenção de uma infecção por hiv, e, uso de uma composição farmacêutica | |
| MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
| BR112014012985A2 (pt) | métodos de conservação de composições farmacêuticas injetáveis compreendendo uma ciclodextrina e uma droga hidrofóbica | |
| CO6400185A2 (es) | Formas de dosificación sólida de bendamustina | |
| HRP20201307T1 (hr) | Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme | |
| Allemailem | Antimicrobial potential of naturally occurring bioactive secondary metabolites | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| WO2021035068A3 (en) | Inhibitors of zika virus infection | |
| RU2020102454A (ru) | Композиции для профилактики и лечения острого повреждения почек | |
| RU2017138118A (ru) | Комбинации противоглистных агентов и способы их применения | |
| Bakar et al. | Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphyloccus aureus | |
| Janeklang et al. | In vitro and in vivo antitumor activity of tiliacorinine in human cholangiocarcinoma | |
| HRP20230820T1 (hr) | Heparan-sulfat, s visokom stopom 3-o-sulfatiranja u glukozaminskim ostacima | |
| WO2021102161A8 (en) | Methods for treating inflammatory bowel disease | |
| EP1609473A8 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria | |
| BRPI0608395A2 (pt) | composição farmacêutica sólida que compreende telitromicina | |
| US20170273938A1 (en) | Use of flavonoids in manufacturing compositions for wound healing | |
| RU2007138266A (ru) | Комбинация ингибитора стероидсульфатазы и аскомицина | |
| JP2016124821A (ja) | 敗血症性脳症用医薬 | |
| RU2560518C1 (ru) | Средство, обладающее лимфокинетической активностью | |
| WO2018024888A8 (en) | Compositions and the use thereof for treating or preventing rosacea | |
| Aykaç et al. | Effects of Chitosan on Cisplatin-Induced Hepatorenal Toxicity in an Animal Model. | |
| Kumar et al. | Efficacy of postoperative antibiotics after appendectomy in patients with non perforated appendicitis-A Clinical Study | |
| US9937193B2 (en) | Method for treating a cancer |